Read by QxMD icon Read

Vascular Calcification

shared collection
158 papers 100 to 500 followers
By Isabel Acosta-Ochoa Nephrology senior staff. Valladolid. Spain
C Salcedo, P H Joubert, M D Ferrer, A Z Canals, F Maduell, V Torregrosa, J M Campistol, R Ojeda, J Perelló
AIMS: SNF472 is a calcification inhibitor that is being studied as a novel treatment for calciphylaxis and cardiovascular calcification (CVC). A first study showed acceptable safety and tolerability in a single ascending dose administration in healthy volunteers and a single dose administration in haemodialysis (HD) patients. This study aimed to assess the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) relationship of intravenous (iv) SNF472 in HD patients in a multiple ascending dose administration trial with 5 doses tested for one week (three administrations) and one dose tested for four weeks (12 administrations)...
January 10, 2019: British Journal of Clinical Pharmacology
Miguel Carracedo, Gonzalo Artiach, Anna Witasp, Joan Clària, Mattias Carlström, Andres Laguna-Fernandez, Peter Stenvinkel, Magnus Bäck
Aims: Vascular calcification, a marker of increased cardiovascular risk, is an active process orchestrated by smooth muscle cells. Observational studies indicate that omega-3 fatty acids protect against vascular calcification, but the mechanisms are unknown. The G-protein coupled receptor ChemR23 transduces the resolution of inflammation induced by the omega-3-derived lipid mediator resolvin E1. ChemR23 also contributes to osteoblastic differentiation of stem cells and bone formation, but its role in vascular calcification is unknown...
December 28, 2018: Cardiovascular Research
Fong-Fu Chou, Jin-Bor Chen, Shun-Cheng Huang, Yi-Chai Chan, Shun-Yu Chi, Wei-Ting Chen
BACKGROUND: Changes of calcification scores of the abdominal aorta (CSAA) after total parathyroidectomy plus autotransplantation (TPX + AT) for symptomatic secondary hyperparathyroidism (SSHP) have never been reported. METHODS: Forty-nine patients who successfully underwent TPX + AT for SSHP were enrolled; 13 patients who had regular hemodialysis were enrolled as controls. Preoperatively, patients' age, gender, and duration of dialysis were recorded. Serum Ca, P, alkaline phosphatase (Alk-ptase), intact parathyroid hormone (iPTH), vitamin D, FGF23, and Klotho levels, and CSAA were measured...
December 18, 2018: American Journal of Surgery
Toshiaki Nakano, Shunsuke Katsuki, Mingxian Chen, Julius L Decano, Arda Halu, Lang Ho Lee, Diego V S Pestana, Angelo S T Kum, Rodrigo K Kuromoto, Whitney S Golden, Mario S Boff, Gabriel C Guimaraes, Hideyuki Higashi, Kevin J Kauffman, Takashi Maejima, Takehiro Suzuki, Hiroshi Iwata, Albert-László Barabási, Jon C Aster, Daniel G Anderson, Amitabh Sharma, Sasha A Singh, Elena Aikawa, Masanori Aikawa
BACKGROUND: Chronic kidney disease (CKD) increases cardiovascular risk. Underlying mechanisms, however, remain obscure. The uremic toxin indoxyl sulfate is an independent cardiovascular risk factor in CKD. We explored the potential impact of indoxyl sulfate on proinflammatory activation of macrophages and its underlying mechanisms. METHODS: We examined in vitro the effects of clinically relevant concentrations of indoxyl sulfate on proinflammatory responses of macrophages and the roles of organic anion transporters and organic anion transporting polypeptides (OATPs)...
January 2, 2019: Circulation
Ying Gao, Guiyun Wang, Yang Li, Chenxiao Lv, Zunsong Wang
BACKGROUND: The relationship between oral activated charcoal (OAC) and hyperphosphatemia and vascular calcification is not completely clear. We observed and recorded the effects of OAC on hyperphosphatemia and vascular calcification in stage 3-4 chronic kidney disease (CKD). METHODS: In a randomized controlled study, we included 97 patients with stage 3-4 CKD. In the first phase of the experiment, the patients were randomly divided into the OAC group and placebo group...
December 26, 2018: Journal of Nephrology
David Ngai, Marsel Lino, Michelle P Bendeck
Vascular calcification is a complex pathological process occurring in patients with atherosclerosis, type 2 diabetes, and chronic kidney disease. The extracellular matrix, via matricrine-receptor signaling plays important roles in the pathogenesis of calcification. Calcification is mediated by osteochondrocytic-like cells that arise from transdifferentiating vascular smooth muscle cells. Recent advances in our understanding of the plasticity of vascular smooth muscle cell and other cells of mesenchymal origin have furthered our understanding of how these cells transdifferentiate into osteochondrocytic-like cells in response to environmental cues...
2018: Frontiers in Cardiovascular Medicine
Seung Hyun Lee, Jae-Hoon Choi
Calcific aortic valve disease (CAVD) is the most common degenerative heart valve disease. Among the many risk factors for this disease are age, hypercholesterolemia, hypertension, smoking, type-2 diabetes, rheumatic fever, and chronic kidney disease. Since many of these overlap with risk factors for atherosclerosis, the molecular and cellular mechanisms of CAVD development have been presumed to be similar to those for atherogenesis. Thus, attempts have been made to evaluate the therapeutic efficacy of statins, representative anti-atherosclerosis drugs with lipid-lowering and anti-inflammatory effects, against CAVD...
2018: Animal Cells and Systems
Marta Cano-Megías, Hanane Bouarich, Pablo Guisado-Vasco, María Pérez Fernández, Gabriel de Arriba-de la Fuente, Concepción Álvarez-Sanz, Diego Rodríguez-Puyol
INTRODUCTION: Patients with chronic kidney disease (CKD) and diabetes mellitus (DM) have high cardiovascular risk. Both conditions are related to systemic atherosclerosis and vascular calcification. The prevalence and severity of coronary artery calcification (CaC) is higher in patients with DM, regardless of their renal function. Data about the long-term prognostic role of CaC in diabetic patients with CKD are scarce. MATERIAL AND METHODS: We carried out a prospective longitudinal study enrolling 137 patients with advanced CKD...
November 30, 2018: Endocrinología, diabetes y nutrición
Andreas Pasch, Willi Jahnen-Dechent, Edward R Smith
Phosphate is an important cardiovascular risk factor and lowering elevated blood phosphate concentrations is a main therapeutic target in kidney patients. Phosphate is subject to the blood mineral buffering system which controls the precipitation of calcium and phosphate. Calciprotein particles (CPP), self-assembling complexes of calcium phosphate and serum proteins, are the nanomorphological correlates of this system. CPP1 are spherical, 50-100 nm in diameter, and contain amorphous mineral. CPP2 are oblongated, 100-200nm in the long axis, and they contain a crystalline mineral core...
2018: International Journal of Nephrology
Jiayi Yan, Luyao Li, Minfang Zhang, Hong Cai, Zhaohui Ni
AIM: To explore the relationship between circulating bone-specific alkaline phosphatase (BALP) levels and abdominal aortic calcification (AAC) in patients receiving maintenance hemodialysis (MHD). METHODS: A total of 156 MHD patients were enrolled. Serum BALP levels were measured using ELISA, and AAC was assessed via lateral abdominal radiography. RESULTS: BALP was positively correlated with AAC score (r = 0.389; p < 0.01). Multivariate logistic regression analysis showed that high-sensitivity C-reactive protein, dialysis vintage and BALP were independent risk factors for AAC in MHD patients...
November 30, 2018: Biomarkers in Medicine
Henry Quiñones, Tamim Hamdi, Khashayar Sakhaee, Andreas Pasch, Orson W Moe, Charles Y C Pak
AIMS: Cardiovascular (CV) complications are common in chronic kidney disease (CKD). Numerous metabolic disturbances including hyperphosphatemia, high circulating calciprotein particles (CPP), hyperparathyroidism, metabolic acidosis, and magnesium deficiency are associated with, and likely pathogenic for CV complications in CKD. The goal of this feasibility study was to determine whether effervescent calcium magnesium citrate (EffCaMgCit) ameliorates the aforementioned pathogenic intermediates...
November 21, 2018: Journal of Nephrology
Shumila Manzoor, Syed Ahmed, Arshad Ali, Kum Hyun Han, Ioannis Sechopoulos, Ansley O'Neill, Baowei Fei, W Charles O'Neill
Introduction: Medial arterial calcification is common in chronic kidney disease (CKD) and portends poor clinical outcomes, but its progression relative to the severity of CKD and the role of other risk factors is unknown because of the lack of reliable quantification. Methods: Calcification of breast arteries detected by mammography, which is exclusively medial and correlates with medial calcification in peripheral arteries and with cardiovascular outcomes, was used to measure the progression of medial arterial calcification in women with CKD and end-stage renal disease (ESRD)...
November 2018: KI Reports
Manuel Jiménez Villodres, Guillermo García Gutiérrez, Patricia García Frías, José Rioja Villodres, Mónica Martín Velázquez, Miguel Ángel Sánchez Chaparro, Carmen Pérez López, Pedro Valdivielso
The role of renal excretion of Pi in relation to vascular calcification (VC) in patients in the early stages of chronic kidney disease (CKD) is controversial. Thus, we determine the relation between fractional excretion of phosphorus (FEP) and VC, measured using two methods in a cross-sectional study of patients with stage 3 CKD. We recorded demographic data, anthropometry, comorbidities and active treatment. We measured 24-hour urine FEP and, in serum, measured fibroblast growth factor 23 (FGF23), α-Klotho, intact parathyroid hormone (iPTH), calcium and phosphorus...
November 14, 2018: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
Thijs T Jansz, Franka E van Reekum, Akin Özyilmaz, Pim A de Jong, Franciscus T J Boereboom, Tiny Hoekstra, Marianne C Verhaar, Brigit C van Jaarsveld
BACKGROUND: Vascular calcification is seen in most patients on dialysis and is strongly associated with cardiovascular mortality. Vascular calcification is promoted by phosphate, which generally reaches higher levels in hemodialysis than in peritoneal dialysis. However, whether vascular calcification develops less in peritoneal dialysis than in hemodialysis is currently unknown. Therefore, we compared coronary artery calcification (CAC), its progression, and calcification biomarkers between patients on hemodialysis and peritoneal dialysis...
2018: American Journal of Nephrology
Beini Lyu, Tanushree Banerjee, Julia J Scialla, Tariq Shafi, Alexander S Yevzlin, Neil R Powe, Rulan S Parekh, Brad C Astor
BACKGROUND: Arteriovenous (AV) access dysfunction is a common complication in hemodialysis patients. Markers of vascular calcification are associated with cardiovascular outcomes and mortality in this population, but their association with vascular access outcomes is unknown. In this study, we aimed to evaluate the association between selected vascular calcification makers and vascular access complications in a cohort of hemodialysis patients. METHOD: Fetuin-A, osteopontin (OPN), osteoprotegerin (OPG), and bone morphogenetic protein-7 (BMP-7) were measured in blood samples from 219 dialysis patients in the Choice for Healthy Outcomes in Caring for end-stage renal disease study; these patients were using a permanent vascular access...
2018: American Journal of Nephrology
V Chaitanya, N Harini Devi, M M Suchitra, P V L N Srinivasa Rao, B Vijaya Lakshmi, V Siva Kumar
The pleiotropic cytokine osteopontin (OPN) is found to be involved in the pathogenesis of both kidney and cardiovascular disease (CVD). We evaluated the relationship between OPN, other cardiovascular risk factors and carotid intima-media thickness (CIMT) in chronic kidney disease (CKD) (predialysis) patients. This is a 2-year cross-sectional prospective study involving 75 patients with CKD from stage 1 to stage 5 attending the nephrology outpatient department and 25 healthy controls. Routine biochemical parameters were analyzed on clinical chemistry Autoanalyzer Beckman Coulter DXC 600 Synchron, USA...
September 2018: Indian Journal of Nephrology
Allison B Reiss, Nobuyuki Miyawaki, Jane Moon, Lora J Kasselman, Iryna Voloshyna, Robert D'Avino, Joshua De Leon
Mineral bone disease (MBD) is a common complication of chronic kidney disease (CKD) characterized by disruption of normal mineral homeostasis within the body. One or more of the following may occur: hypocalcemia, hyperphosphatemia, secondary hyperparathyroidism (SHPT), decreased vitamin D and vascular calcification (VC). The greater the decrease in renal function, the worse the progression of CKD-MBD. These abnormalities may lead to bone loss, osteoporosis and fractures. CKD-MBD is a major contributor to the high morbidity and mortality among patients with CKD...
November 2018: Atherosclerosis
Georg Schlieper
Cardiovascular calcification is still a major burden for patients with chronic kidney disease (CKD). The pathomechanism of vascular calcification is complex, involving numerous processes. In this issue, Yamada et al. describe a protective role of Pit-2 within this context by using PiT-2 heterozygous mice with CKD fed a high-phosphate diet. The mechanisms still need to be elucidated. Pit-2 could become a potential therapeutic target.
October 2018: Kidney International
Yuji Shiozaki, Kayo Okamura, Shohei Kohno, Audrey L Keenan, Kristina Williams, Xiaoyun Zhao, Wallace S Chick, Shinobu Miyazaki-Anzai, Makoto Miyazaki
Vascular calcification (or mineralization) is a common complication of chronic kidney disease (CKD) and is closely associated with increased mortality and morbidity rates. We recently reported that activation of the activating transcription factor 4 (ATF4) pathway through the saturated fatty acid (SFA)-induced endoplasmic reticulum (ER) stress response plays a causative role in CKD-associated vascular calcification. Here, using mouse models of CKD, we 1) studied the contribution of the proapoptotic transcription factor CCAAT enhancer-binding protein homologous protein (CHOP) to CKD-dependent medial calcification, and 2) we identified an additional regulator of ER stress-mediated CHOP expression...
November 2, 2018: Journal of Biological Chemistry
Najwa Skafi, Dina Abdallah, Christophe Soulage, Sophie Reibel, Nicolas Vitale, Eva Hamade, Wissam Faour, David Magne, Bassam Badran, Nader Hussein, Rene Buchet, Leyre Brizuela, Saida Mebarek
Vascular calcification (VC) is the pathological accumulation of calcium phosphate crystals in one of the layers of blood vessels, leading to loss of elasticity and causing severe calcification in vessels. Medial calcification is mostly seen in patients with chronic kidney disease (CKD) and diabetes. Identification of key enzymes and their actions during calcification will contribute to understand the onset of pathological calcification. Phospholipase D (PLD1, PLD2) is active at the earlier steps of mineralization in osteoblasts and chondrocytes...
September 12, 2018: Journal of Cellular Physiology
2018-09-14 07:22:59
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"